Healthcare company, Sanofi, and investment major, Blackstone, have reportedly announced a strategic collaboration focused on accelerating the pivotal studies and clinical development program for subcutaneous formulation as well as delivery of Sarclisa®, an anti-CD38 antibody that can be used for treating multiple myeloma (MM).
As part of the collaboration, funds being managed by Blackstone Life Sciences (BXLS) would be contributing up to €300 million ($330 million) for the proposed acceleration of the studies. As a result, BXLS would be eligible for receiving royalties from subcutaneous sales in the future.
The study for the formulation is expected to start from the second half of this year.
Multiple myeloma is a common form of hematologic malignancy with no cure in existence, causing most patients to relapse. CD38, being uniformly and highly expressed on MM cells’ surface, acts as a potential target for Sarclisa® and similar antibody-based therapeutics.
For the delivery of the Sarclisa® subcutaneous formulation, the Paris-based firm has partnered with Enable Injections, Inc., a drug delivery tech innovator, that will take the development of the antibody’s subcutaneous delivery further with a focus on providing a unique treatment experience that is centered around the patient.
Currently, Sarclisa® has received regulatory approval for intravenous administration for treating certain patients suffering from relapsed MM. The candidate is also being investigated across the multiple myeloma treatment continuum of care for treating solid tumors or other hematologic malignancies.
John Reed, Global Head of Research and Development, Sanofi, stated that the collaboration will help in advancing the firm’s ability to offer an innovative and convenient subcutaneous anti-CD38 antibody therapy to patients.
Reed added that the company is committed to developing a sustainable and industry-leading pipeline and providing a continuous stream of therapies that can help in transforming medicine practice.
Nicholas Galakatos, Global Head, Blackstone Life Sciences, stated that the firm’s investment signifies Blackstone’s commitment as well as ability in offering innovative finance sources to leading pharma firms, adding that it offers capital and expertise for advancing key medicines in major areas of therapy.
Source credit: https://www.globenewswire.com/news-release/2022/03/15/2403030/0/en/Sanofi-announces-300-million-collaboration-with-Blackstone-Life-Sciences-to-advance-an-innovative-treatment-for-multiple-myeloma.html